Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients

Hermans, Michel P.; Brichard, Sonia; Colin, Ides M.; Borgies, P.; Ketelslegers, Jean‐Marie; Lambert, Ae.

doi:10.1016/0002-9343(92)90158-8

Cited by 31 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The differences in systolic and diastolic blood pressure levels between the two groups (placebo and captopril) studied were small, suggesting that ACE inhibitors have a renal protective effect independent of their antihypertensive effect. There are studies showing that in patients with microalbuminuria (urinary albumin excretion rate [UAER] 30 -300 mg/24 h) and hypertension, ACE inhibitors decrease the progression to overt proteinuria (UAER Ͼ300 mg/24 h) (56,57). Also, in studies of type 1 patients with microalbuminuria without a clinical diagnosis of hypertension, several small clinical trials suggest that ACE inhibitors may be beneficial in delaying or preventing the progression of nephropathy (58,59).…”

Section: Effects Of Antihypertensive Drugs On Microvascular Complicatmentioning

confidence: 99%

The Treatment of Hypertension in Adult Patients With Diabetes

2002

View full text Add to dashboard Cite

Section: Effects Of Antihypertensive Drugs On Microvascular Complicatmentioning

confidence: 99%

The Treatment of Hypertension in Adult Patients With Diabetes

2002

View full text Add to dashboard Cite

“…Diabetic nephropathy is the leading cause of end‐stage renal disease in the United States . Angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are known to delay the progression of diabetic nephropathy . For this reason, the American Diabetes Association clinical practice guidelines recommend ACEI/ARB therapy for patients with diabetes mellitus and hypertension and/or albuminuria .…”

mentioning

confidence: 99%

Relationship Between Medication Adherence and Distance to Dispensing Pharmacies and Prescribers Among an Urban Medicaid Population with Diabetes Mellitus

et al. 2016

View full text Add to dashboard Cite

Study Objective To determine whether a relationship exists between medication adherence to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and distance to dispensing pharmacies and prescribers among an urban, public aid population with diabetes mellitus. Design Retrospective cohort study using claims data. Data Source Illinois Department of Healthcare and Family Services database. Patients A total of 6532 patients aged 18–64 years with diabetes who had at least one prescription fill for an ACEI or ARB, and had continuous Medicaid coverage in the greater Chicago area in 2009. Measurements and Main Results Medication adherence, defined as proportion of days covered (PDC) ≥ 0.8, to ACEIs and ARBs and its association with distances between patients and their pharmacies and prescribers was assessed. Of the 6532 patients included in the analyses, 2930 (45%) had PDC levels ≥ 0.8. No significant differences were observed between patients who were adherent versus those who were nonadherent in distance to pharmacy (median 1.39 vs 1.35 miles, p=0.15) or distance to prescriber (median 4.39 vs 4.48 miles, p=0.80). In a multivariate regression model including age, sex, race-ethnicity, number of pharmacies, number of prescribers, distance to pharmacy, and distance to prescriber, a greater number of prescribers was associated with higher adherence (2 prescribers vs 1 prescriber: odds ratio [OR] 1.396, 95% confidence interval [CI] 1.233–1.580; ≥ 3 prescribers vs 1 prescriber: OR 2.208, 95% CI 1.787–2.727). Conclusion ACEI or ARB adherence was not associated with distances to pharmacies and prescribers.

show abstract

“…Taguma et al (10) observed that captopril, an ACE inhibitor, decreased proteinuria in diabetic patients without reducing systemic BP, which suggests that this effect may be the result of a decrease in intrarenal hypertension. Studies by Bauer et al (11), Kelleher (12), Mathiesen et al (13), and Hermans et al (14) suggest that ACE inhibitors have the specific advantages of decreasing proteinuria and slowing the progression of diabetic nephropathy. However, these studies mainly involved IDDM patients and/or short-term observations.…”

mentioning

confidence: 99%